Obsessive-compulsive disorder, impulse control disorders and drug addiction: Common features and potential treatments

Drugs

Volumn 71, Issue 7, 2011, Pages 827-840

  Fontenelle, Leonardo F ^a,b   Oostermeijer, Sanne ^a   Harrison, Ben J ^a   Pantelis, Christos ^a   Ycel, Murat ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Baclofen; Buprenorphine; Impulse control disorders; Naltrexone; Obsessive compulsive disorders; Ondansetron; Substance related disorders; Topiramate

Indexed keywords

ALCOHOL; AMPHETAMINE; BACLOFEN; BUPRENORPHINE; CAFFEINE; COCAINE; DOPAMINE 1 RECEPTOR; NALTREXONE; NEUROTRANSMITTER; NICOTINE; ONDANSETRON; OPIATE; OPIATE ANTAGONIST; PLACEBO; SARCOGLYCAN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; TOPIRAMATE;

ALCOHOLISM; ANXIETY DISORDER; BRAIN REGION; CLINICAL FEATURE; COGNITION; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); CORPUS STRIATUM; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG MEGADOSE; DRUG TARGETING; EATING DISORDER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GILLES DE LA TOURETTE SYNDROME; HUMAN; IMPULSE CONTROL DISORDER; MOLECULAR GENETICS; NERVE CELL NETWORK; NEUROCHEMISTRY; NEUROIMAGING; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PATHOPHYSIOLOGY; REVIEW; SYMPTOM;

ANIMALS; COMORBIDITY; HUMANS; IMPULSE CONTROL DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; SUBSTANCE-RELATED DISORDERS;

EID: 79956135149     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11591790-000000000-00000     Document Type: Review

References (119)

1. John CE, McCracken CB, Haber SN. Motivation on the Mediterranean: reward, compulsions and habit formation. Neurosci Biobehav Rev 2010 Jan; 34 (1): 2-6.
2. Fineberg NA, Potenza MN, Chamberlain SR, et al. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology 2010 Feb; 35 (3): 591-604.
3. Rasmussen SA, Eisen JL. Clinical and epidemiologic findings of significance to neuropharmacologic trials in OCD. Psychopharmacol Bull 1988; 24 (3): 466-470. (Pubitemid 19031638)
4. Ferrao YA, Miguel E, Stein DJ. Tourette's syndrome, trichotillomania, and obsessive-compulsive disorder: how closely are they related? Psychiatry Res 2009 Nov 30; 170 (1): 32-42.
5. Vö llstadt-Klein S, Wichert S, Rabinstein J, et al. Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum. Addiction 2010 Oct; 105 (10): 1741-1749.
6. Eisen JL, Rasmussen SA. Coexisting obsessive compulsive disorder and alcoholism. J Clin Psychiatry 1989 Mar; 50 (3): 96-98. (Pubitemid 19095868)
7. Friedman I, Dar R, Shilony E. Compulsivity and obsessionality in opioid addiction. J Nerv Ment Dis 2000 Mar; 188 (3): 155-162. (Pubitemid 30159866)
8. Mancebo MC, Grant JE, Pinto A, et al. Substance use disorders in an obsessive compulsive disorder clinical sample. J Anxiety Disord 2009 May; 23 (4): 429-435.
9. Grant JE, Mancebo MC, Pinto A, et al. Impulse control disorders in adults with obsessive compulsive disorder. J Psychiatr Res 2006 Sep; 40 (6): 494-501. (Pubitemid 44175412)
10. Fontenelle LF, Mendlowicz MV, Versiani M. Impulse control disorders in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci 2005 Feb; 59 (1): 30-37. (Pubitemid 40314490)
11. Kü hn S, Gallinat J. Common biology of craving across legal and illegal drugs: a quantitative meta-analysis of cuereactivity brain response. Eur J Neurosci 2011 Apr; 33 (7): 1318-1326.
12. McGuire PK, Bench CJ, Frith CD, et al. Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 1994 Apr; 164 (4): 459-468. (Pubitemid 24141670)
13. Rauch SL, Jenike MA, Alpert NM, et al. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 1994 Jan; 51 (1): 62-70. (Pubitemid 24028999)
14. Breiter HC, Rauch SL, Kwong KK, et al. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry 1996 Jul; 53 (7): 595-606. (Pubitemid 26240862)
15. Mataix-Cols D, Wooderson S, Lawrence N, et al. Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder. Arch Gen Psychiatry 2004 Jun; 61 (6): 564-576. (Pubitemid 38747311)
16. Schienle A, Schafer A, Stark R, et al. Neural responses of OCD patients towards disorder-relevant, generally disgustinducing and fear-inducing pictures. Int J Psychophysiol 2005 Jul; 57 (1): 69-77. (Pubitemid 40776118)
17. Rauch SL, Shin LM, Dougherty DD, et al. Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 2002 Nov; 27 (5): 782-791. (Pubitemid 35335894)
18. Kober H, Mende-Siedlecki P, Kross EF, et al. Prefrontalstriatal pathway underlies cognitive regulation of craving. Proc Natl Acad Sci USA 2010 Aug 17; 107 (33): 14811-4816.
19. Nakao T, Nakagawa A, Yoshiura T, et al. Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biol Psychiatry 2005 Apr 15; 57 (8): 901-910. (Pubitemid 40488359)
20. Rotge JY, Guehl D, Dilharreguy B, et al. Provocation of obsessive-compulsive symptoms: a quantitative voxelbased meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci 2008 Sep; 33 (5): 405-412.
21. Chamberlain SR, Menzies L, Hampshire A, et al. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 2008 Jul 18; 321 (5887): 421-422. (Pubitemid 352029981)
22. Freyer T, Kloppel S, Tuscher O, et al. Frontostriatal activation in patients with obsessive-compulsive disorder before and after cognitive behavioral therapy. Psychol Med 2011 Jan; 41 (1): 207-216.
23. de Ruiter MB, Veltman DJ, Goudriaan AE, et al. Response perseveration and ventral prefrontal sensitivity to reward and punishment in male problem gamblers and smokers. Neuropsychopharmacology 2009 Mar; 34 (4): 1027-1038.
24. Page LA, Rubia K, Deeley Q, et al. A functional magnetic resonance imaging study of inhibitory control in obsessivecompulsive disorder. Psychiatry Res 2009 Dec 30; 174 (3): 202-209.
25. Yucel M, Lubman DI. Neurocognitive and neuroimaging evidence of behavioural dysregulation in human drug addiction: implications for diagnosis, treatment and prevention. Drug Alcohol Rev 2007 Jan; 26 (1): 33-39.
26. Yucel M, Lubman DI, Solowij N, et al. Understanding drug addiction: a neuropsychological perspective. Aust N Z J Psychiatry 2007 Dec; 41 (12): 957-968. (Pubitemid 350120825)
27. Feil J, Sheppard D, Fitzgerald PB, et al. Addiction, compulsive drug seeking, and the role of frontostriatal mechanisms in regulating inhibitory control. Neurosci Biobehav Rev 2010 Nov; 35 (2): 248-275.
28. Hester R, Lubman DI, Yucel M. The role of executive control in human drug addiction. Curr Top Behav Neurosci 2010; 3: 301-318.
29. Potenza MN, Steinberg MA, Skudlarski P, et al. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2003 Aug; 60 (8): 828-836. (Pubitemid 36960914)
30. Dannon PN, Kushnir T, Aizer A, et al. Alternation learning in pathological gamblers: an fMRI Study. Brain Imaging Behav 2011 Mar; 5 (1): 45-51.
31. Coccaro EF, McCloskey MS, Fitzgerald DA, et al. Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression. Biol Psychiatry 2007 Jul 15; 62 (2): 168-178. (Pubitemid 46963248)
32. Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005 Feb; 8 (2): 147-148. (Pubitemid 40194043)
33. Goldstein RZ, Tomasi D, Alia-Klein N, et al. Subjective sensitivity to monetary gradients is associated with frontolimbic activation to reward in cocaine abusers. Drug Alcohol Depend 2007 Mar 16; 87 (2-3): 233-240. (Pubitemid 46215930)
34. Figee M, Vink M, de Geus F, et al. Dysfunctional reward circuitry in obsessive-compulsive disorder [abstract]. European Neuropsychopharmacology 2010; 20 Suppl. 3: S302.
35. Muller UJ, Sturm V, Voges J, et al. Successful treatment of chronic resistant alcoholism by deep brain stimulation of nucleus accumbens: first experience with three cases. Pharmacopsychiatry 2009 Nov; 42 (6): 288-291.
36. Mantione M, van de Brink W, Schuurman PR, et al. Smoking cessation and weight loss after chronic deep brain stimulation of the nucleus accumbens: therapeutic and research implications: case report. Neurosurgery 2010 Jan; 66 (1): E218; discussion E218.
37. Harrison BJ, Soriano-Mas C, Pujol J, et al. Altered corticostriatal functional connectivity in obsessive-compulsive disorder. Arch Gen Psychiatry 2009 Nov; 66 (11): 1189-1200.
38. Ma N, Liu Y, Li N, et al. Addiction related alteration in resting-state brain connectivity. Neuroimage 2010 Jan 1; 49 (1): 738-744.
39. Baxter Jr LR, Phelps ME, Mazziotta JC, et al. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987 Mar; 44 (3): 211-218. (Pubitemid 17023134)
40. Baxter Jr LR, Schwartz JM, Mazziotta JC, et al. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 1988 Dec; 145 (12): 1560-1563. (Pubitemid 19009706)
41. Nordahl TE, Benkelfat C, Semple WE, et al. Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology 1989 Mar; 2 (1): 23-28. (Pubitemid 19126156)
42. Perani D, Colombo C, Bressi S, et al. [18F]FDG PET study in obsessive-compulsive disorder: a clinical/metabolic correlation study after treatment. Br J Psychiatry 1995 Feb; 166 (2): 244-250.
43. Kwon JS, Kim JJ, Lee DW, et al. Neural correlates of clinical symptoms and cognitive dysfunctions in obsessivecompulsive disorder. Psychiatry Res 2003 Jan 20; 122 (1): 37-47. (Pubitemid 36183551)
44. Pallanti S, Haznedar MM, Hollander E, et al. Basal ganglia activity in pathological gambling: a fluorodeoxyglucosepositron emission tomography study. Neuropsychobiology 2010; 62 (2): 132-138.
45. Schiffer WK, Lee DE, Brodie JD, et al. Imaging addiction with PET: is insight in sight? Drug Discov Today 2005 Apr 15; 10 (8): 547-562. (Pubitemid 40544797)
46. van den Heuvel OA, van der Werf YD, Verhoef KM, et al. Frontal-striatal abnormalities underlying behaviours in the compulsive-impulsive spectrum. J Neurol Sci 2010 Feb 15; 289 (1-2): 55-59.
47. Bechara A, Tranel D, Damasio H, et al. Failure to respond autonomically to anticipated future outcomes following damage to prefrontal cortex. Cereb Cortex 1996 Mar- Apr; 6 (2): 215-225. (Pubitemid 26117399)
48. Barbey AK, Koenigs M, Grafman J. Orbitofrontal contributions to human working memory. Cereb Cortex 2010 Apr; 21 (4): 789-795.
49. Aron AR, Fletcher PC, Bullmore ET, et al. Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci 2003 Feb; 6 (2): 115-116. (Pubitemid 36182778)
50. Owen AM, Downes JJ, Sahakian BJ, et al. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 1990; 28 (10): 1021-1034. (Pubitemid 20347464)
51. Frey S, Petrides M. Orbitofrontal cortex: a key prefrontal region for encoding information. ProcNatlAcad SciUS A 2000 Jul 18; 97 (15): 8723-8727. (Pubitemid 30639740)
52. Clarke HF,Dalley JW, Crofts HS, et al. Cognitive inflexibility after prefrontal serotonin depletion. Science 2004May 7; 304 (5672): 878-880. (Pubitemid 38620188)
53. Cavedini P, Gorini A, Bellodi L. Understanding obsessivecompulsive disorder: focus on decision making. Neuropsychol Rev 2006 Mar; 16 (1): 3-15. (Pubitemid 43954074)
54. Papageorgiou C, Rabavilas A, Liappas I, et al. Do obsessive- compulsive patients and abstinent heroin addicts share a common psychophysiological mechanism? Neuropsychobiology 2003; 47 (1): 1-11. (Pubitemid 36469779)
55. Chamberlain SR, Fineberg NA, Blackwell AD, et al. Motor inhibition and cognitive flexibility in obsessivecompulsive disorder and trichotillomania. Am J Psychiatry 2006 Jul; 163 (7): 1282-1284. (Pubitemid 44464460)
56. Chamberlain SR, Fineberg NA, Menzies LA, et al. Impaired cognitive flexibility and motor inhibition in unaffected first-degree relatives of patients with obsessivecompulsive disorder. Am J Psychiatry 2007 Feb; 164 (2): 335-338.
57. Chamberlain SR, Fineberg NA, Blackwell AD, et al. A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania. Neuropsychologia 2007Mar 2; 45 (4): 654-662. (Pubitemid 46001411)
58. Chamberlain SR, Blackwell AD, Fineberg NA, et al. Strategy implementation in obsessive-compulsive disorder and trichotillomania. Psychol Med 2006 Jan; 36 (1): 91-97. (Pubitemid 41825349)
59. Westenberg HG, Fineberg NA, Denys D. Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectr 2007 Feb; 12 (2 Suppl. 3): 14-27.
60. Carlsson ML. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001 Jan; 25 (1): 5-26. (Pubitemid 32173787)
61. McDougle CJ, Barr LC, Goodman WK, et al. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 1999 Jan; 24 (1): 1-24. (Pubitemid 29057017)
62. Roy BF, Benkelfat C, Hill JL, et al. Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection. Biol Psychiatry 1994 Mar 1; 35 (5): 335-344. (Pubitemid 24150269)
63. Weizman R, Gil-Ad I, Hermesh H, et al. Immunoreactive beta-endorphin, cortisol, and growth hormone plasma levels in obsessive-compulsive disorder. Clin Neuropharmacol 1990 Aug; 13 (4): 297-302. (Pubitemid 20230324)
64. Leckman JF, Riddle MA, Berrettini WH, et al. Elevated CSF dynorphin A [1-8] in Tourette's syndrome. Life Sci 1988; 43 (24): 2015-2023.
65. Nurnberg HG, Keith SJ, Paxton DM. Consideration of the relevance of ethological animal models for human repetitive behavioral spectrum disorders. Biol Psychiatry 1997 Jan 15; 41 (2): 226-229. (Pubitemid 27062664)
66. Nestadt G, Samuels J, Riddle M, et al. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry 2000 Apr; 57 (4): 358-363. (Pubitemid 30202326)
67. Hanna GL, Fischer DJ, Chadha KR, et al. Familial and sporadic subtypes of early-onset obsessive-compulsive disorder. Biol Psychiatry 2005 Apr 15; 57 (8): 895-900. (Pubitemid 40488358)
68. Mangold DL, Peyrot M, Giggey P, et al. Endogenous opioid activity is associated with obsessive-compulsive symptomology in individuals with a family history of alcoholism. Neuropsychopharmacology 2000 Jun; 22 (6): 595-607. (Pubitemid 30219403)
69. Hess CW, Raymond D, Aguiar Pde C, et al. Myoclonusdystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology 2007 Feb 13; 68 (7): 522-524.
70. Urraca N, Camarena B,Gomez-Caudillo L, et al.Mu opioid receptor gene as a candidate for the study of obsessive compulsive disorder with and without tics. Am J Med Genet B Neuropsychiatr Genet 2004 May 15; 127B (1): 94-96. (Pubitemid 38542322)
71. Hollander E, Wong CM. Obsessive-compulsive spectrum disorders. J Clin Psychiatry 1995; 56 Suppl. 4: 3-6; discussion 53-55.
72. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010 Jan; 35 (1): 217-238.
73. Belin D, Mar AC, Dalley JW, et al. High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008 Jun 6; 320 (5881): 1352-1355. (Pubitemid 351929473)
74. Everitt BJ, Belin D, Economidou D, et al. Review: neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci 2008 Oct 12; 363 (1507): 3125-3135.
75. Endrass T, Kloft L, Kaufmann C, et al. Approach and avoidance learning in obsessive-compulsive disorder. Depress Anxiety 2011 Feb; 28 (2): 166-172.
76. Greenberg BD, Gabriels LA, Malone Jr DA, et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry 2010 Jan; 15 (1): 64-79.
77. Johnson BA. Medication treatment of different types of alcoholism. Am J Psychiatry 2010 Jun; 167 (6): 630-639.
78. Fontenelle LF, Nascimento AL, Mendlowicz MV, et al. An update on the pharmacological treatment of obsessivecompulsive disorder. Expert Opin Pharmacother 2007 Apr; 8 (5): 563-583. (Pubitemid 46547011)
79. Hantouche EG, Demonfaucon C. Resistant obsessive compulsive disorder (ROC): clinical picture, predictive factors and influence of affective temperaments [in French]. Encephale 2008 Dec; 34 (6): 611-617.
80. Dell'Osso B, Hollander E. The impact of comorbidity on the management of pathological gambling. CNS Spectr 2005 Aug; 10 (8): 619-621. (Pubitemid 41232542)
81. Rojas-Corrales MO, Gibert-Rahola J, Mico JA. Role of atypical opiates in OCD: experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior. Psychopharmacology (Berl) 2007 Feb; 190 (2): 221-231. (Pubitemid 46011182)
82. Insel TR, Pickar D. Naloxone administration in obsessivecompulsive disorder: report of two cases. Am J Psychiatry 1983 Sep; 140 (9): 1219-1220. (Pubitemid 13050743)
83. Keuler DJ, Altemus M, Michelson D, et al. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry 1996 Jul 15; 40 (2): 154-156. (Pubitemid 26202448)
84. Goldsmith TB, Shapira NA, Keck Jr PE. Rapid remission of OCD with tramadol hydrochloride. Am J Psychiatry 1999 Apr; 156 (4): 660-661. (Pubitemid 29162995)
85. Shapira NA, Keck Jr PE, Goldsmith TD, et al. Open-label pilot study of tramadol hydrochloride in treatmentrefractory obsessive-compulsive disorder. Depress Anxiety 1997; 6 (4): 170-173. (Pubitemid 28164822)
86. Koran LM, Aboujaoude E, Bullock KD, et al. Doubleblind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2005 Mar; 66 (3): 353-359. (Pubitemid 40476759)
87. Khazaal Y, Krenz S, Benmebarek M, et al. Worsening of obsessive-compulsive symptoms under methadone tapering. Prog Neuropsychopharmacol Biol Psychiatry 2006 Sep 30; 30 (7): 1350-1352. (Pubitemid 44216053)
88. Senjo M. Obsessive-compulsive disorder in people that abuse codeine. Acta Psychiatr Scand 1989 Jun; 79 (6): 619-620. (Pubitemid 19168609)
89. Amiaz R, Fostick L, Gershon A, et al. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008 Jun; 18 (6): 455-461.
90. Hamidi A, Jahanguiri B, EsfahaniMN, et al. Naltrexone in obsessive-compulsive disorder: an open- label trial. Iran J Psychiatry Behav Sci 2007; 1 (1): 16-21.
91. Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome. Int J Neurosci 1987 Jul; 35 (1-2): 93-94.
92. Chappell PB, Leckman JF, Riddle MA, et al. Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. Adv Neurol 1992; 58: 253-262.
93. Hollander E, Dell'Osso B. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 2006 May; 21 (3): 189-191. (Pubitemid 43740312)
94. Rubio G, Jimenez-Arriero MA, Martinez-Gras I, et al. The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2006 Jun; 26 (3): 341-344. (Pubitemid 43804634)
95. Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. Epub 2010 Aug 10.
96. Mowla A. Does topiramate adjunction have any effect on obsessions and compulsions in patient with obsessive compulsive disorder? [abstract]. Eur Psychiatry 2010; 25 Suppl. 1: 358.
97. Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 2003 Sep; 64 (9): 1025-1030. (Pubitemid 37158247)
98. Pallanti S, Bernardi S, Antonini S, et al. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 2009 Dec 1; 23 (12): 1047-1055.
99. SingerHS,Wendlandt J,KriegerM, et al. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 2001Mar 13; 56 (5): 599-604. (Pubitemid 32209991)
100. Albucher RC, Curtis GC. Adderall for obsessive-compulsive disorder. Am J Psychiatry 2001 May; 158 (5): 818-819.
101. Owley T, Owley S, Leventhal B, et al. Case series: adderall augmentation of serotonin reuptake inhibitors in childhood- onset obsessive compulsive disorder. J Child Adolesc Psychopharmacol 2002 Summer; 12 (2): 165-171. (Pubitemid 34779030)
102. Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2009 Nov; 70 (11): 1530-1535.
103. Kaplan A, Hollander E. Comorbidity in compulsive hoarding: a case report. CNS Spectr 2004 Jan; 9 (1): 71-73. (Pubitemid 38419010)
104. Soyka M, Rosner S. Opioid antagonists for pharmacological treatment of alcohol dependence: a critical review. Curr Drug Abuse Rev 2008 Nov; 1 (3): 280-291.
105. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005 Jun; 8 (2): 267-280. (Pubitemid 40769268)
106. Grant JE, Kim SW, Hartman BK. A double-blind, placebocontrolled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 2008 May; 69 (5): 783-789. (Pubitemid 351838687)
107. Kurlan R, Majumdar L, Deeley C, et al. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. Ann Neurol 1991 Jul; 30 (1): 19-23.
108. Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr Dis Treat 2006 Dec; 2 (4): 475-488. (Pubitemid 46321877)
109. Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 2010 May; 71 (5): 634-648.
110. Dannon PN, Lowengrub K, Gonopolski Y, et al. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005 Jan-Feb; 28 (1): 6-10. (Pubitemid 40269711)
111. Arbaizar B, Gomez-Acebo I, Llorca J. Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry 2008 Sep-Oct; 30 (5): 471-475.
112. Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010 Jan; 81 (1): 70-73.
113. Ye JH, Ponnudurai R, Schaefer R. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 2001 Summer; 7 (2): 199-213. (Pubitemid 32656301)
114. Kenna GA, Zywiak WH, McGeary JE, et al. A withingroup design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res 2009 Feb; 33 (2): 315-323.
115. Toren P, Weizman A, Ratner S, et al. Ondansetron treatment in Tourette's disorder: a 3-week, randomized, doubleblind, placebo-controlled study. J Clin Psychiatry 2005 Apr; 66 (4): 499-503. (Pubitemid 40593579)
116. Marshall FH. Is the GABA B heterodimer a good drug target? J Mol Neurosci 2005; 26 (2-3): 169-176.
117. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007 Dec 8; 370 (9603): 1915-1922. (Pubitemid 350192657)
118. Stahl SM. Mechanism of action of stimulants in attentiondeficit/ hyperactivity disorder. J Clin Psychiatry 2010 Jan; 71 (1): 12-13.
119. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010 Apr; 19 (4): 353-64